HUE027179T2 - Angiogenezis és vasculogenesis modulátor Rspondinek - Google Patents
Angiogenezis és vasculogenesis modulátor Rspondinek Download PDFInfo
- Publication number
- HUE027179T2 HUE027179T2 HUE07819170A HUE07819170A HUE027179T2 HU E027179 T2 HUE027179 T2 HU E027179T2 HU E07819170 A HUE07819170 A HU E07819170A HU E07819170 A HUE07819170 A HU E07819170A HU E027179 T2 HUE027179 T2 HU E027179T2
- Authority
- HU
- Hungary
- Prior art keywords
- rspondin
- angiogenesis
- antibody
- arg
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pathology (AREA)
Claims (3)
- Aagiogemzls és vaseufogenests modulátor Rspondinek Szabadalmi igénypontok1, Egy Rspondírfo vagy 3 pokpegtld vagy egy Rspondin2 vagy 3 nukleinsav alkalmazása patológiás állapot kezelésem szolgáló gyógyszer előállításában, ahol a kezelés az angiogenesis és/vagy vasculogenesls elősegítését használja ki
- 3. Az: i, igénypont szerbül alkalmazás sebgyógyulás, szerv regeneráció vagy kiíc-dodes. embrió fejlődés és/vagy repodnkelos folyamat elősegítésére vagy degenerativ folyamatok, különösen vasculodegenerntiv folyamatok, például ischemias folyamatok, példán! kritikus végtag ischemia, agyi ischemia vagy ischemias szívbetegség gátlására,
- 3, Egy Rspondúfo vagy 3: aníagonista alkalmazása angiogenesis és/vagy vaseulogenesis elő-segítésén alapuló, patológiás állapot kezelésére szolgáló gyógyszer előállításában, ahol az antagonists egy aníi-Rspondin 2 vagy anti-Rsponilna amitest vagy egy antiszensz; molekula vagy SÍRNA molekula, 4, Â 3, igénypont szerinti alkalmazás, ahol aRspondio2 vagy 3 antagonists egy aníRRspondm 2 antitest. 5, .A 3. igén> pmu szerinti alkalmazás, ahol a Rspondirfo vagy 3 antagonists egy arfo~Rspoodm 3 antitest, 4 A 4-5. igénypontok bármelyike szerinti alkalmazás, ahol az antitest egy rekombináns pollkfonális, monoklonáils, kimer, humanizált vagy egyláneú antitest vagy íragmense. 1. A 4-6, igénypontok bármehike szerinti alkalmazás:, ahol az antitest egy rnonoklonáhs antitest, S. A 4-4 Igénypontok bármelyike szerinti alkalmazás, aboi az antitest egy humanizált antitest. 9. À 3·»8. igénypontok bármelyike szerinti alkalmazás olya« állapotok megelőzésére vagy kezelésére, ahol a kezelés angiogenezis és/vagy vasculogenesis gátlásával jár, különösen tumor növekedés, elsősorban szilárd tumor növekedés, rheumatoid arthritis, atherosclerosis, stenosis, restenosis, retinopathia, xnaeuiaxis degeoeráelé vagy psoriasis kezelésére.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06022070 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027179T2 true HUE027179T2 (hu) | 2016-10-28 |
Family
ID=39149425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE07819170A HUE027179T2 (hu) | 2006-10-20 | 2007-10-19 | Angiogenezis és vasculogenesis modulátor Rspondinek |
Country Status (13)
Country | Link |
---|---|
US (6) | US8088374B2 (hu) |
EP (2) | EP2997975A1 (hu) |
JP (2) | JP5777281B2 (hu) |
AU (1) | AU2007312538B2 (hu) |
CA (1) | CA2664828A1 (hu) |
DK (1) | DK2081586T4 (hu) |
ES (1) | ES2564794T5 (hu) |
HK (1) | HK1222799A1 (hu) |
HU (1) | HUE027179T2 (hu) |
MX (1) | MX2009003726A (hu) |
PL (1) | PL2081586T5 (hu) |
SI (1) | SI2081586T2 (hu) |
WO (1) | WO2008046649A1 (hu) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1673475T3 (da) | 2003-10-10 | 2010-07-19 | Deutsches Krebsforsch | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt |
SI2081586T2 (sl) † | 2006-10-20 | 2019-01-31 | Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts | Rspondini kot modulatorji angiogeneze in vaskulogeneze |
PL3009148T3 (pl) | 2007-07-02 | 2019-03-29 | Oncomed Pharmaceuticals, Inc. | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu |
US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
EP3441458B9 (en) | 2009-02-03 | 2023-08-23 | Koninklijke Nederlandse Akademie van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells |
WO2010121923A1 (en) * | 2009-04-15 | 2010-10-28 | Deutsches Krebsforschungszentrum | Rspondin-3 inhibition in bone disorders |
EP2977060A1 (en) * | 2009-12-23 | 2016-01-27 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
CA2841745A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
AU2013204484B2 (en) * | 2011-07-15 | 2016-05-12 | Oncomed Pharmaceuticals, Inc. | RSPO binding agents and uses thereof |
EP2791320A4 (en) * | 2011-12-14 | 2015-05-27 | Univ Leland Stanford Junior | STIMULATION OF OVARIAN FOLLICLE DEVELOPMENT AND OOCYTE MATURATION |
BR112014019741A2 (pt) * | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
WO2014012007A2 (en) * | 2012-07-13 | 2014-01-16 | Oncomed Pharmaceuticals, Inc. | Rspo3 binding agents and uses thereof |
MX2016004802A (es) * | 2013-10-18 | 2016-07-18 | Genentech Inc | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. |
US10597633B2 (en) | 2014-05-16 | 2020-03-24 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture method for organoids |
EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
GB201421092D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
WO2021080396A1 (ko) * | 2019-10-24 | 2021-04-29 | 가톨릭대학교 산학협력단 | Rspo3 억제제를 포함하는 심장 판막 질환의 예방 또는 치료용 조성물 |
WO2022020544A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Method of treating an inflammatory condition |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO2003094843A2 (en) | 2002-05-10 | 2003-11-20 | Incyte Corporation | Cell adhesion and extracellular matrix proteins |
WO1998041539A2 (en) | 1997-03-19 | 1998-09-24 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
JP2001527403A (ja) | 1997-04-25 | 2001-12-25 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
GB9828419D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel compounds |
JP2003505082A (ja) | 1999-07-26 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 新規なポリヌクレオチドとその使用法 |
AU6181000A (en) | 1999-07-29 | 2001-02-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel genes encoding protein kinase/protein phosphatase |
US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
US6653448B1 (en) | 2000-03-29 | 2003-11-25 | Curagen Corporation | Wnt-7B-like polypeptides and nucleic acids encoding same |
WO2001077169A2 (en) | 2000-04-05 | 2001-10-18 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20030022255A1 (en) | 2000-12-22 | 2003-01-30 | Morris David W. | Novel compositions and methods for breast cancer |
JP2005503108A (ja) | 2001-01-31 | 2005-02-03 | インサイト・ゲノミックス・インコーポレイテッド | タンパク質修飾およびメンテナンス分子 |
US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
EP1383789A2 (en) | 2001-04-06 | 2004-01-28 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
WO2002100898A2 (en) | 2001-06-11 | 2002-12-19 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
WO2003027230A2 (en) | 2001-08-03 | 2003-04-03 | Incyte Genomics, Inc. | Cell adhesion and extracellular matrix proteins |
EP1427747B1 (en) | 2001-08-30 | 2012-04-11 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
WO2003025142A2 (en) | 2001-09-16 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and secreted polypeptides |
US7439332B2 (en) | 2002-04-26 | 2008-10-21 | Kirin Pharma Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells |
CA2500521A1 (en) | 2002-10-02 | 2004-09-23 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2004099408A1 (ja) | 2003-05-09 | 2004-11-18 | Research Association For Biotechnology | 新規蛋白質およびそれをコードするdna |
WO2005110009A2 (en) * | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
DK1673475T3 (da) | 2003-10-10 | 2010-07-19 | Deutsches Krebsforsch | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt |
WO2005071058A2 (en) | 2004-01-27 | 2005-08-04 | Compugen Ltd. | Methods and systems for annotating biomolecular sequences |
US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
WO2007013666A2 (en) * | 2005-07-26 | 2007-02-01 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
WO2007100357A2 (en) | 2005-10-07 | 2007-09-07 | Nuvelo, Inc. | Stem cell factor-like protein scfa1 and uses thereof |
JP2008044926A (ja) * | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
SI2081586T2 (sl) * | 2006-10-20 | 2019-01-31 | Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts | Rspondini kot modulatorji angiogeneze in vaskulogeneze |
PL3009148T3 (pl) | 2007-07-02 | 2019-03-29 | Oncomed Pharmaceuticals, Inc. | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu |
CA2841745A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
-
2007
- 2007-10-19 SI SI200731757T patent/SI2081586T2/sl unknown
- 2007-10-19 EP EP15190671.6A patent/EP2997975A1/en not_active Withdrawn
- 2007-10-19 WO PCT/EP2007/009105 patent/WO2008046649A1/en active Application Filing
- 2007-10-19 PL PL07819170T patent/PL2081586T5/pl unknown
- 2007-10-19 ES ES07819170T patent/ES2564794T5/es active Active
- 2007-10-19 CA CA002664828A patent/CA2664828A1/en not_active Abandoned
- 2007-10-19 MX MX2009003726A patent/MX2009003726A/es active IP Right Grant
- 2007-10-19 AU AU2007312538A patent/AU2007312538B2/en not_active Ceased
- 2007-10-19 DK DK07819170.7T patent/DK2081586T4/en active
- 2007-10-19 JP JP2009532732A patent/JP5777281B2/ja not_active Expired - Fee Related
- 2007-10-19 US US12/311,921 patent/US8088374B2/en not_active Expired - Fee Related
- 2007-10-19 HU HUE07819170A patent/HUE027179T2/hu unknown
- 2007-10-19 EP EP07819170.7A patent/EP2081586B2/en not_active Not-in-force
-
2011
- 2011-12-01 US US13/309,193 patent/US8580736B2/en not_active Expired - Fee Related
-
2013
- 2013-10-08 US US14/048,225 patent/US8926970B2/en not_active Expired - Fee Related
- 2013-11-29 JP JP2013247353A patent/JP5822897B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-07 US US14/453,692 patent/US9226963B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/870,846 patent/US10273276B2/en not_active Expired - Fee Related
-
2016
- 2016-09-21 HK HK16111049.0A patent/HK1222799A1/zh unknown
-
2019
- 2019-03-19 US US16/357,765 patent/US10538563B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10538563B2 (en) | Rspondins as modulators of angiogenesis and vasculogenesis | |
JP2011523551A (ja) | 血管形成の調節の新規ターゲット | |
US20120039912A1 (en) | Rspondin-3 inhibition in bone disorders | |
CA2530582A1 (en) | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis | |
JP2008237022A (ja) | 非小細胞肺がんの予防・治療剤および診断薬 | |
JP2010131022A (ja) | Dnaマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット | |
JP5704722B2 (ja) | 細胞接着阻害剤およびその用途 | |
US7138512B2 (en) | Gene SHINC-2 and diagnostic and therapeutic uses thereof | |
JPH11503620A (ja) | 神経アポトーシス抑制性蛋白質(naip)の使用 | |
JP2007224009A (ja) | 癌の予防・治療剤 | |
WO2001096359A1 (en) | Compositions, methods, and kits relating to resistin-like molecules | |
US20090312245A1 (en) | SRA binding protein | |
JP2001517954A (ja) | Noey2遺伝子組成物およびその使用方法 | |
JP4353697B2 (ja) | がんの予防・治療剤 | |
JPWO2005061704A1 (ja) | 癌の予防・治療剤 | |
JPWO2006101273A1 (ja) | 癌の予防・治療剤 | |
JP2005151826A (ja) | C1qtnf5の用途 |